Synthesis and Biological Evaluation of Gem‐Difluoromethylenated Statin Derivatives as Highly Potent HMG‐CoA Reductase Inhibitors
Authors:
- 15 June 2016
- journal article
- research article
- Published by Wiley in Chinese Journal of Chemistry
- Vol. 34 (8) , 801-808
Abstract
HMG‐CoA reductase inhibitors were widely used as lipid‐lowing agents through effectively blocking the rate‐limiting step of cholesterol biosynthesis. 8 analogs of Rosuvastatin were firstly prepared with different distance and functional group between the O5‐hydroxyl group and terminal COOH group in the hydrophilic side‐chain. In primary and secondary screening of the inhibitory activities against human HMG‐CoA reductase, gem‐difluoromethylenated derivatives exhibited more than 50% inhibition rate. Then 4 compounds with gem‐difluoro group were further synthesized and evaluated in vitro, three compounds among them exhibited low single digital nmol/L IC50 values against HMG‐CoA reductase. Molecular docking also well explained the observed special contribution of the gem‐difluoro group.Keywords
Funding Information
- National Natural Science Foundation of China (21502117, 21172148)
- Shanghai Municipal Education Commission (Plateau Discipline Construction Program)
This publication has 23 references indexed in Scilit:
- Therapeutic Potential of Mipomersen in the Management of Familial HypercholesterolaemiaDrugs, 2012
- Synthesis of γ,γ-difluoro-β-hydroxy-δ-lactones as new precursors of HMG-CoA reductase inhibitorJournal of Fluorine Chemistry, 2012
- Statins therapy: a review on conventional and novel formulation approachesJournal of Pharmacy and Pharmacology, 2011
- Development of an Early Enabling Synthesis for PF-03052334-02: A Novel Hepatoselective HMG-CoA Reductase InhibitorOrganic Process Research & Development, 2010
- Synthesis and HMG-CoA reductase inhibition of 2-cyclopropyl-4-thiophenyl-quinoline mevalonolactonesBioorganic & Medicinal Chemistry, 2009
- (3R,5S,E)-7-(4-(4-Fluorophenyl)-6-isopropyl-2-(methyl(1-methyl-1H-1,2,4-triazol-5-yl)amino)pyrimidin-5-yl)-3,5-dihydroxyhept-6-enoic Acid (BMS-644950): A Rationally Designed Orally Efficacious 3-Hydroxy-3-methylglutaryl Coenzyme-A Reductase Inhibitor with Reduced Myotoxicity PotentialJournal of Medicinal Chemistry, 2008
- Hepatoselectivity of statins: Design and synthesis of 4-sulfamoyl pyrroles as HMG-CoA reductase inhibitorsBioorganic & Medicinal Chemistry Letters, 2008
- Substituted Pyrazoles as Hepatoselective HMG-CoA Reductase Inhibitors: Discovery of (3R,5R)-7-[2-(4-Fluoro-phenyl)-4-isopropyl-5-(4-methyl-benzylcarbamoyl)-2H-pyrazol-3-yl]-3,5-dihydroxyheptanoic Acid (PF-3052334) as a Candidate for the Treatment of HypercholesterolemiaJournal of Medicinal Chemistry, 2007
- Fluorine in Pharmaceuticals: Looking Beyond IntuitionScience, 2007
- Structural Mechanism for Statin Inhibition of HMG-CoA ReductaseScience, 2001